Precigen (NASDAQ:PGEN) Issues Earnings Results

Precigen (NASDAQ:PGEN) issued its quarterly earnings results on Tuesday. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06, FiscalAI reports. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The firm had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.98 million. The business’s revenue for the quarter was up 6322.7% on a year-over-year basis.

Here are the key takeaways from Precigen’s conference call:

• PAPZIMEOS revenue surged to $53.1 million in Q2 from $21.6 million in Q1, a more than 145% sequential increase that drove Precigen to quarterly net income of $20.1 million, or $0.05 per diluted share.
• Commercial adoption continued to broaden, with more than 500 patients registered through PAPZIMEOS SUPPORT, approximately 315 million covered U.S. lives, and increasing use across major medical centers and community practices. Management said the permanent J-code effective April 1 has helped institutions establish routine reimbursement and treatment workflows.
• Management highlighted a broad FDA label, favorable safety profile, and durability data showing 83% of patients remained in complete response beyond three years as of the April 30 cutoff, with some patients exceeding four years without additional RRP treatment. PAPZIMEOS also received seven-year U.S. market exclusivity through August 2032.
• Precigen expects PAPZIMEOS gross margins to stabilize in the high-80% to low-90% range after remaining pre-launch inventory is sold, while R&D spending is expected to rise as pipeline programs advance. The company said cash, investments, and collection of receivables should fund operations through cash-flow breakeven by the end of 2026.
• The company remains on track to begin a pediatric PAPZIMEOS trial this year, while its EMA marketing application is under review. PRGN-2009 continues in Phase 2 trials with pembrolizumab in HPV-related head and neck and cervical cancers, with updated head-and-neck data expected later in 2026.

Precigen Trading Up 6.4%

NASDAQ PGEN traded up $0.42 during trading on Wednesday, hitting $6.95. 6,767,621 shares of the company’s stock traded hands, compared to its average volume of 4,512,991. The stock has a fifty day moving average of $5.07 and a two-hundred day moving average of $4.44. Precigen has a 12-month low of $1.70 and a 12-month high of $7.23. The firm has a market cap of $2.48 billion, a P/E ratio of -5.89 and a beta of 1.02. The company has a debt-to-equity ratio of 4.62, a current ratio of 4.82 and a quick ratio of 4.12.

Precigen News Summary

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 results: Precigen reported earnings of $0.05 per share, versus analyst expectations for a loss of approximately $0.01–$0.02, while revenue surged to $54.98 million from $23.25 million a year earlier and exceeded estimates near $28 million. The company also reported $20.1 million in net income attributable to common shareholders. Precigen Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: PAPZIMEOS commercial momentum: PAPZIMEOS generated $53.1 million in second-quarter net revenue, more than double the prior quarter. Patient-hub enrollment exceeded 500 patients, suggesting expanding adoption, while management said revenue and available funds are expected to support cash-flow break-even by year-end 2026. FDA-granted seven-year market exclusivity also improves the product’s competitive protection. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst support: HC Wainwright reiterated its Buy rating and maintained a $14 price target, well above recent trading levels. The firm’s endorsement may strengthen investor confidence after the earnings beat. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusual options activity: Investors purchased 27,256 call options, roughly 790% above average daily call volume. This signals heightened speculative interest and potentially bullish positioning, but options activity does not guarantee sustained buying in the shares. Precigen Target of Unusually Large Options Trading
• Negative Sentiment: Insider selling: COO Rutul Shah sold 33,772 shares for approximately $219,518 under a pre-arranged Rule 10b5-1 plan. Broader reported insider activity shows sales and no purchases over the past six months, which may weigh on sentiment, although planned transactions are not necessarily discretionary bearish signals. Precigen COO Insider Sale

Analysts Set New Price Targets

PGEN has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research report on Friday, July 17th. Citizens Jmp boosted their target price on Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Citigroup reiterated an “outperform” rating on shares of Precigen in a research report on Thursday, May 14th. Finally, HC Wainwright lifted their price target on shares of Precigen from $14.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $14.50.

Insider Buying and Selling

In other news, COO Rutul R. Shah sold 42,924 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.85, for a total value of $251,105.40. Following the completion of the sale, the chief operating officer owned 497,751 shares of the company’s stock, valued at approximately $2,911,843.35. The trade was a 7.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Harry Jr. Thomasian sold 171,429 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $5.53, for a total value of $948,002.37. Following the sale, the chief financial officer owned 354,535 shares of the company’s stock, valued at $1,960,578.55. This represents a 32.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 956,500 shares of company stock worth $5,248,371 in the last ninety days. Corporate insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Mason Investment Advisory Services Inc. bought a new position in shares of Precigen in the fourth quarter worth approximately $42,000. Abel Hall LLC bought a new stake in Precigen during the 4th quarter valued at $44,000. NewEdge Advisors LLC bought a new stake in Precigen during the 4th quarter valued at $45,000. Caitong International Asset Management Co. Ltd purchased a new stake in Precigen during the 3rd quarter valued at $39,000. Finally, Cibc World Markets Corp purchased a new stake in Precigen during the 4th quarter valued at $50,000. Institutional investors own 33.51% of the company’s stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.